Schrodinger Share Price Today

TD Cowen raises Schrodinger price target to $36, maintains Buy rating

TD Cowen raised Schrodinger's price target to $36. The previous target was set at $31. Analyst Brendan Smith maintained a Buy rating. The target increase amounts to $5 per share.

Schrodinger Q3FY26 Results: ACV rises 17% to $44.7 million

ACV rose 17% YoY to $44.7 million, with 24% growth excluding contribution ACV. Total revenue increased 19% to $64.5 million; hosted software revenue jumped 49%. Drug discovery revenue surged to $24.2 million on Structure Therapeutics milestone. Net loss widened to $38 million due to $11.4 million equity mark-to-market expense. Full-year 2026 ACV guidance raised to $222–$232 million.

Keybanc maintains Overweight on Schrodinger, lifts price target to $32

Keybanc maintains an Overweight rating on Schrodinger. Price target raised from $20 to $32 by analyst Scott Schoenhaus. The new target represents a 60% increase from the previous level.

Schrodinger Latest Results: Drug Discovery Revenue Guided At $65M-$75M

Schrodinger forecasts drug discovery revenue between $65 million and $75 million for the fiscal year. This guidance highlights the importance of the segment to the company’s financial performance. Investors should monitor actual results against this range to assess execution.